Results of the TWENTE trial reported at TCT 2011

November 11, 2011, Cardiovascular Research Foundation

The TWENTE clinical trial, which compared two second generation drug-eluting stents – zotarolimus and everolimus-eluting stents – established non-inferiority between the two stents as measured by the primary endpoint: target vessel failure (TVF) at one year. Both stents also demonstrated low rates of stent thrombosis. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Early trials with first generation drug-eluting (DES) have demonstrated a reduction in restenosis rates compared to bare metal stents, but not lower mortality. One of the factors thought to be involved in this, is the lack of biocompatibility of coating on first generation stents, some of which were thought to be associated with hypersensitivity and vessel wall inflammation which can promote stent thrombosis. Second generation drug-eluting stents with improved coatings were developed to improve biocompatibility.

While more than two million drug-eluting stents are implanted annually worldwide (the majority of which is second generation DES), there are very few trials with a head-to-head comparison of second generation drug-eluting stents in 'real-world' patient populations.

The TWENTE study is a prospective, single-blinded, randomized controlled trial in patients requiring percutaneous coronary interventions (PCI) with drug-eluting stent implantation for the treatment of chronic stable coronary artery disease or acute coronary syndromes. To allow for the inclusion of a broad patient population as seen in routine clinical practice, the study protocol defined no limit for lesion length, reference vessel size, and number of lesions or vessels to be treated. Patients with ST‐elevation myocardial infarction requiring primary or rescue percutaneous coronary interventions during the past 48 hours were not eligible.

A total of 1,391 patients were enrolled, 82% of all eligible patients. The study population (age 64.3± 10.5 years; 72.5% male) included 21.6% diabetics. Patients presented with either stable angina (48.5%) or unstable angina/Non-STEMI (51.5%). Follow up information was obtained on 100% of the patients.

TVF at one year occurred in 8.2% of patients for the zotarolimus-eluting stent, and in 8.1% of patients for the everolimus-eluting stent (p=0.94). For the components of the primary endpoint, there were also no significant differences: cardiac death (1.0% vs. 1.4%, p=0.46), target vessel-related myocardial infarction (4.6% vs. 4.6%, p=0.98), and clinically driven target vessel revascularization (3.3% vs. 2.7%, p=0.53).

TWENTE showed similar and – considering the complexity of the patient population and the lesion characteristics – relatively low one-year rates of definite-plus-probable stent thrombosis for the zotarolimus and everolimus-eluting stents (0.86% and 1.16%, respectively). TWENTE also showed a low definite one-year stent thrombosis rate for zotarolimus and everolimus-eluting stents (0.58% and 0%, respectively).

"Results of the TWENTE trial show that zotarolimus-eluting stents were non-inferior to everolimus-eluting stents in terms of safety and efficacy for treating 'real-world' patients with a vast majority of complex lesions and 'off-label' indications for drug-eluting stents, which were implanted with liberal use of postdilatation," said Clemens von Birgelen, MD PhD, the Principal Investigator of the trial. Dr. von Birgelen is Co-Director of the Department of Cardiology at Thoraxcentrum Twente and Professor of Cardiology at University of Twente in the Netherlands.

"The liberal use of stent postdilatation, applied in 82% of lesions, could have contributed to the positive results in both stent arms, despite the complex patient and lesion population examined in this trial," Dr. von Birgelen said.

TWENTE is the second published randomized study with minimal exclusion criteria to compare both stents head-to-head and it confirms the findings of the first study. Clinical events were scored by the same independent, external research organization as the first comparative study. Event rates in TWENTE were slightly lower.

"TWENTE did not have a STEMI subpopulation (STEMI is the most serious form of heart attack), but this does not explain the positive TWENTE results, as the STEMI subpopulation in the first comparative trial actually had lower clinical event rates than the overall population of that trial," Dr. von Birgelen said.

Explore further: Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent

Related Stories

Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent

August 30, 2011
The second generation drug-eluting stent Xience V performs well in patients having primary PCI for ST elevation myocardial infarction, and has a better safety profile than that of bare metal stents, according to results of ...

Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents

August 29, 2011
The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting ...

Results of the DEB-AMI Trial reported at TCT 2011

November 10, 2011
A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary ...

Results of the DESERT registry reported at TCT 2011

November 9, 2011
The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at ...

An 'important' reduction in risk of stent thrombosis with everolimus-eluting stent

August 30, 2011
Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an "important" reduction in overall and very late stent thrombosis. The reduction in incidence was found when a newer generation everolimus-eluting ...

Recommended for you

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

Place of residence linked to heart failure risk

January 9, 2018
Location. Location. Location.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.